AGFB Stock Overview
Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||€3.71|
|52 Week High||€4.59|
|52 Week Low||€2.92|
|1 Month Change||-4.26%|
|3 Month Change||3.34%|
|1 Year Change||-2.37%|
|3 Year Change||-1.49%|
|5 Year Change||-11.01%|
|Change since IPO||-82.71%|
Recent News & Updates
|AGFB||BE Healthcare Services||BE Market|
Return vs Industry: AGFB exceeded the Belgian Healthcare Services industry which returned -20.2% over the past year.
Return vs Market: AGFB underperformed the Belgian Market which returned -1.4% over the past year.
|AGFB Average Weekly Movement||5.3%|
|Healthcare Services Industry Average Movement||7.5%|
|Market Average Movement||5.2%|
|10% most volatile stocks in BE Market||7.9%|
|10% least volatile stocks in BE Market||3.1%|
Stable Share Price: AGFB is not significantly more volatile than the rest of Belgian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AGFB's weekly volatility (5%) has been stable over the past year.
About the Company
Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company’s Offset Solutions segment provides commercial, newspaper, and packaging printers; integrated prepress and printing solutions, including computer-to-plate systems using digital offset printing plates, pressroom supplies, and software for workflow optimization, color management, screening, and print standardization; and security printing software solutions. Its Radiology Solutions segment offers analog and digital imaging technology for diagnostic imaging market to meet the needs of specialized clinicians in hospitals and imaging centers; and X-ray film, hardcopy film and printers, digital radiography equipment, and image processing software.
Agfa-Gevaert Fundamentals Summary
|AGFB fundamental statistics|
Is AGFB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGFB income statement (TTM)|
|Cost of Revenue||€1.29b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 24, 2022
|Earnings per share (EPS)||-0.10|
|Net Profit Margin||-0.89%|
How did AGFB perform over the long term?See historical performance and comparison
Is Agfa-Gevaert undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AGFB (€3.71) is trading below our estimate of fair value (€10.11)
Significantly Below Fair Value: AGFB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AGFB is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.
PE vs Market: AGFB is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGFB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGFB is good value based on its PB Ratio (0.9x) compared to the XE Healthcare Services industry average (2.8x).
How is Agfa-Gevaert forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AGFB's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if AGFB's earnings are forecast to grow faster than the Belgian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AGFB's revenue is expected to decline over the next 3 years (-3.3% per year).
High Growth Revenue: AGFB's revenue is forecast to decline over the next 3 years (-3.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGFB's Return on Equity is forecast to be high in 3 years time
How has Agfa-Gevaert performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGFB is currently unprofitable.
Growing Profit Margin: AGFB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGFB is unprofitable, and losses have increased over the past 5 years at a rate of 48.1% per year.
Accelerating Growth: Unable to compare AGFB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGFB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).
Return on Equity
High ROE: AGFB has a negative Return on Equity (-2.06%), as it is currently unprofitable.
How is Agfa-Gevaert's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AGFB's short term assets (€1.4B) exceed its short term liabilities (€630.0M).
Long Term Liabilities: AGFB's short term assets (€1.4B) exceed its long term liabilities (€804.0M).
Debt to Equity History and Analysis
Debt Level: AGFB has more cash than its total debt.
Reducing Debt: AGFB's debt to equity ratio has reduced from 37.3% to 10% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGFB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AGFB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Agfa-Gevaert current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGFB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGFB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGFB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGFB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AGFB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Juery (56 yo)
Mr. Pascal Juéry serves as Chief Executive Officer at Agfa-Gevaert NV since February 1, 2020 and also serves as its President since 2020. Mr. Juéry serves as a Director of Agfa-Gevaert NV since 2020 and al...
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD1.25M) is above average for companies of similar size in the Belgian market ($USD802.79K).
Compensation vs Earnings: Pascal's compensation has increased whilst the company is unprofitable.
Experienced Management: AGFB's management team is considered experienced (3.1 years average tenure).
Experienced Board: AGFB's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Agfa-Gevaert NV's employee growth, exchange listings and data sources
- Name: Agfa-Gevaert NV
- Ticker: AGFB
- Exchange: ENXTBR
- Founded: 1867
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: €580.167m
- Shares outstanding: 156.38m
- Website: https://www.agfa.com
Number of Employees
- Agfa-Gevaert NV
- Septestraat 27
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.